Leerink Partnrs Has Negative Forecast for UTHR Q2 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for United Therapeutics in a report issued on Wednesday, July 23rd. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of $7.25 per share for the quarter, down from their prior estimate of $8.08. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.31 EPS, Q4 2025 earnings at $6.97 EPS, FY2025 earnings at $28.16 EPS, FY2026 earnings at $29.26 EPS, FY2027 earnings at $28.69 EPS and FY2028 earnings at $30.05 EPS.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. During the same period in the previous year, the company posted $6.17 EPS. United Therapeutics’s revenue was up 17.2% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on UTHR. UBS Group dropped their target price on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a report on Monday, June 30th. Wall Street Zen downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Bank of America decreased their target price on United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research report on Wednesday, June 11th. Finally, JPMorgan Chase & Co. dropped their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $383.08.

United Therapeutics Trading Down 0.6%

NASDAQ UTHR opened at $304.50 on Friday. The stock has a market capitalization of $13.74 billion, a price-to-earnings ratio of 12.15, a PEG ratio of 6.68 and a beta of 0.53. The business’s 50 day moving average is $300.01 and its two-hundred day moving average is $316.20. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $417.82.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at about $29,000. SVB Wealth LLC purchased a new position in United Therapeutics in the first quarter valued at approximately $32,000. Dunhill Financial LLC raised its holdings in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 50 shares during the period. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Finally, Sound Income Strategies LLC purchased a new stake in United Therapeutics during the first quarter worth approximately $49,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $11,185,469.91. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock valued at $24,628,589 over the last quarter. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.